Sorafenib and Radiotherapy in the Treatment of Invasive Bladder Cancer With Conservative Intent
Safety profile and to determine maximum tolerated dose of Sorafenib in combination with Radiotherapy in the Treatment of Invasive Bladder Cancer With Conservative Intent
Bladder Cancer
DRUG: Sorafenib|PROCEDURE: Radiotherapy
Safety profile of Sorafenib in combination with Radiotherapy., 12 weeks|Maximum tolerated dose of Sorafenib in combination with Radiotherapy., 12 weeks
Study phase I in patients with Invasive Bladder Cancer